Quantcast

Latest Allergic Rhinitis Stories

2011-04-27 07:00:00

ST. PAUL, Minn., April 27, 2011 /PRNewswire/ -- Patients with asthma or allergic rhinitis (nasal allergies), initially prescribed montelukast (Singulair®) instead of typical first-line therapy have low rates of persistence on montelukast and may ultimately discontinue therapy altogether, according to a new study presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting in Minneapolis, Minn. The study will be presented by Prime Therapeutics (Prime), a thought...

2011-03-21 16:47:00

SAN FRANCISCO, March 21, 2011 /PRNewswire/ -- Results from a recent pivotal allergic rhinitis (AR) satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities. Findings from the Nasal Allergy Survey Assessing Limitations (NASL) 2010, released today by Teva Respiratory at the American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, held in San...

2011-03-21 11:45:00

SAN FRANCISCO, March 21, 2011 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis. The results demonstrated statistically significant...

2010-12-14 06:30:00

IRVINE, Calif., Dec. 14, 2010 /PRNewswire/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has initiated a Phase 2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of bepotastine besilate, dosed twice daily, in patients presenting...

2010-10-07 07:00:00

SAN DIEGO and SEATTLE, Oct. 7 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis. The results demonstrated that VTX-1463 significantly improved allergy symptoms based on Total Nasal Symptom...

2010-10-06 06:30:00

IRVINE, Calif., Oct. 6 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive preliminary results from a Phase 1/2 clinical study of bepotastine besilate nasal spray conducted in Canada for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The findings demonstrated two of the three bepotastine besilate concentrations tested were effective in relieving patients' nasal...

2010-09-06 13:55:00

ANTONY, France, September 6, 2010 /PRNewswire-FirstCall/ -- Stallergenes S.A. has announced today the signing of exclusive partnership agreements with Shionogi & Co., Ltd. for two sublingual allergen immunotherapy tablet products resulting from the Stalair(R) program: Actair(R) house dust mite tablets and Japanese cedar pollen tablets. With 32 million respiratory allergy sufferers, there is a strong - and as yet unmet - demand for treatment in Japan, where sublingual allergen...

2010-07-28 09:45:00

HORSHAM, Pa., July 28 /PRNewswire/ -- Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo. "The outcomes of the...

2010-07-14 06:30:00

IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has initiated a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group study will evaluate the safety and efficacy of three concentrations of bepotastine besilate, dosed twice daily, in an...

2010-06-28 13:54:00

ANTONY, France, June 28, 2010 /PRNewswire-FirstCall/ -- After having announced positive results for the first year of its phase IIb/III clinical trial (VO 57.07) conducted on Actair(R) sublingual allergen immunotherapy tablets in allergic rhinitis triggered by house dust mites in April 2009, Stallergenes S.A. today announces the results of the second year of this study. Following this first year which demonstrated positive results for both the dosages tested (300 IR[1] and 500 IR)...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related